Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure
Francesca Alberton,Laura Galli,Riccardo Lolatto,Caterina Candela,Nicola Gianotti,Matteo Chiurlo,Martina Ranzenigo,Martina Strano,Alessia Uglietti,Antonella Castagna
DOI: https://doi.org/10.2147/dddt.s443775
IF: 4.3188
2024-04-10
Drug Design Development and Therapy
Abstract:Francesca Alberton, 1 Laura Galli, 2 Riccardo Lolatto, 2 Caterina Candela, 1 Nicola Gianotti, 2 Matteo Chiurlo, 2 Martina Ranzenigo, 2 Martina Strano, 2 Alessia Uglietti, 3 Antonella Castagna 1, 2 1 Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy; 2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy; 3 Medical Affairs Department, Infectious Diseases and Vaccines & Rare Diseases, Johnson&Johnson, Milan, Italy Correspondence: Alessia Uglietti, Medical Affairs Department, Infectious Disease and Vaccines & Rare Diseases, Johnson&Johnson, viale Fulvio Testi 280/6, Milan, 20126, Italy, Tel +39-344 2665502, Email Objective: To evaluate the virological outcome of darunavir–cobicistat (DRVc)‐based regimens in adults living with HIV who had experienced virological failure (VF) on any previous drug combination. Methods: This was a retrospective cohort study (CSLHIV Cohort) of adults living with HIV who started a DRVc‐based regimen with HIV‐RNA > 50 copies/mL after VF on any previous drug combination. Data on demographics, antiretroviral treatment since HIV diagnosis, and immunological and metabolic parameters from baseline (start of DRVc) to 48 weeks were analyzed in order to assess the cumulative proportion of those who achieved virological success (VS), defined as at least one instance of HIV‐RNA < 50 copies/mL within 12 months from baseline. Follow-up lasted from the start of the DRVc-based regimen (baseline) to the first instance of HIV-RNA < 50 copies/mL, last available visit, or loss to follow‐up or death, whichever occurred first. Univariate and multivariate Cox proportional-hazard regression models were used to identify baseline factors associated with VS. Results: A total of 176 individuals were included, and 120 (68.2%) achieved < 50 HIV‐RNA copies/mL within 12 months since baseline. On multivariate analysis, baseline HDL cholesterol was independently associated with the occurrence of VS (adjusted HR 1.021, 95% CI 1.004– 1.038; p =0.014). Among the 120 subjects with VS, 27 (22.5%) had had VF during a median follow-up of 20.8 months since the first undetectable HIV-RNA. Resistance testing after VF was available in two cases, which harboured the HIV variant–bearing protease inhibitor–resistance mutations D30N, I50V, and N88D. During a median follow-up of 38.4 months, 65 of 176 (36.9%) individuals discontinued DRVc for any reason (37 of 120, 30.8%) and achieved VS vs. 28 of 56 (50%) without VS ( p =0.019). Time to discontinuation was longer in people with VS (41.5 vs. 23.0 months, p =0.0007). No statistically significant changes were observed in immunological or lipid profiles during follow-up. Conclusion: Most individuals in this study achieved VS within 12 months from the beginning of a DRVc-based regimen; therefore, this treatment represent a viable option for people who have experienced VF on other regimens. Keywords: HIV infection, antiretroviral therapy, ART, darunavir–cobicistat, DRVc, virological failure, VF Boosted darunavir (bDRV) is included in international guidelines for HIV1-infection therapy, both for treatment-naïve and treatment-experienced people, and in cases of virological failure (VF) with single- or multiclass resistance, as long as it proves to be fully active and in combination with at least another active drug. 1 Ritonavir-boosted DRV (DRVr) 600/100 mg twice daily has proved to be highly effective in HIV-infected, treatment-experienced individuals showing VF and primary protease inhibitor (PI)-resistance mutations. 2,3 It was later demonstrated that once-daily DRVr 800/100 mg was as effective as DRVr 600/100 mg twice daily in treatment-experienced patients with no DRV resistance-associated mutations, with a lower incidence of lipid profile worsening. 4 A fixed-dose formulation of DRV–cobicistat (DRVc) was next developed and a once-daily single-tablet formulation of DRVc–emtricitabine (FTC)–tenofovir alafenamide (TAF) showed efficacy, a high barrier to resistance, tolerability, and bone and renal function safety benefits in treatment-naïve HIV1 patients. 5 For these reasons, DRVc currently represents a natural choice for people living with HIV (PLWH) developing VF under non–nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimens, integrase strand-transfer inhibitor (InSTI)-based regimens, or most PI-based regimens, thanks to the absence of cross-resistance. However, data on the efficacy of DRVc as a rescue drug are very scarce, 6,7 as most of the data (even recent) come from clinical studies where DRV was -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal